Browsing: Nordisk

By Ankika Biswas (Reuters) -Europe’s closed slightly higher at the start of a holiday-shortened week, as a spike in Novo…

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN(Reuters) -Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients…

By Suzanne McGee (Reuters) – Three separate asset management firms launched exchange-traded funds on Tuesday, unveiling products focused on securitized…

Investing.com — Novo Nordisk (CSE:) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches…

Investing.com — Bank of America (BofA) adjusted its price objective for Novo Nordisk (NYSE:) shares to DKK1075 from the previous…

By Maggie Fick and Patrick Wingrove LONDON/NEW YORK (Reuters) – As Eli Lilly (NYSE:)’s weight-loss drug Zepbound gains ground in…

By Ahmed Aboulenein WASHINGTON (Reuters) -Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk (NYSE:) can be convinced to…

LONDON (Reuters) – Shares in Novo Nordisk (NYSE:), maker of the wildly popular obesity drug Wegovy, were down 1.9% on…

Novo Nordisk investors appeared unperturbed Thursday by a critical Harvard report that linked weight loss drugs to a rare eye…

By Andrew Silver SHANGHAI (Reuters) – Novo Nordisk (NYSE:) is facing the prospect of intensifying competition in the promising Chinese…